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Abstract
Pseudolymphoma is a benign lymphocytic tumor-like lesion, and its occurrence in the liver is rare. Here, we
report the case of a 78-year-old woman with pseudolymphoma of the liver. She had a history of tremors for
several years. Therefore, she underwent computed tomography (CT) for screening, and liver tumors were
incidentally identified. She did not have any history of liver disease. Liver function test results and tumor marker
levels were all within normal limits, and viral markers for hepatitis were negative. Contrast-enhanced CT revealed
four nodules measuring up to 13 mm in diameter with ring enhancement in both lobes of the liver. On magnetic
resonance imaging, the lesions showed slightly high intensity on T2-weighted images and high intensity on
diffusion-weighted images. Because of atypical imaging findings, the tumors could not be definitively diagnosed.
Therefore, we performed laparoscopic limited resection of segments 2, 3, 4, and 8 of the liver. The final
pathological diagnosis was pseudolymphoma of the liver. The patient has had no signs of recurrence for
6 months after the surgery. Although pseudolymphoma of the liver is rare, it is necessary to consider it in the
differential diagnosis of a liver tumor.
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Background
Pseudolymphoma or reactive lymphoid hyperplasia is a
benign nonspecific lesion characterized by a marked pro-
liferation of polyclonal lymphocytes forming follicles with
an active germinal center [1, 2]. Although pseudolym-
phoma has been reported in various organs, including the
skin [3], lungs [4, 5], eye orbit [6], intestine [7–9], and
thyroid [10], its occurrence in the liver is rare. The eti-
ology of pseudolymphoma is yet unknown, and it has been
speculated to represent a reactive immunological response
to a chronic infection or inflammatory process [11]. In
addition, its association with malignancy has been re-
ported [2]. The preoperative diagnosis of pseudolym-
phoma is difficult because the imaging findings are usually
equivocal. Herein, we report the case of a patient with
pseudolymphoma of the liver.
Case presentation
A 78-year-old woman with a history of tremors for sev-
eral years presented to the Department of Neurology in
our hospital. She was admitted to our hospital, and she
underwent computed tomography (CT) for screening.
The CT scan incidentally revealed multiple lesions in the
liver; therefore, a qualitative diagnosis was required.
The results of laboratory examinations, including liver
function tests, were all within normal limits. The results
were as follows: white blood cell count, 6940/mm3;
hemoglobin level, 14.1 g/dL; platelet count, 20.8 × 104/
mm3; serum aspartate aminotransferase level, 21 IU/L;
serum alanine aminotransferase level, 19 IU/L; alkaline
phosphatase level, 204 IU/L; γ-glutamyl transpeptidase
level, 37 IU/L; and total bilirubin level, 1.0 mg/dL. The
levels of tumor markers, including alpha-fetoprotein, a pro-
tein induced by vitamin K absence, carcinoembryonic anti-
gen, carbohydrate antigen 19-9, and soluble interleukin-2
receptor, were all within normal limits. Viral markers for
hepatitis B and C were negative. Levels of immunoglobulin
(Ig) G, including IgG4, IgA, and IgM were normal. Tests
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for antinuclear antibody, anti-DNA antibody, and anti-
smooth muscle antibody were negative.
Imaging revealed four nodules measuring up to 13 mm
in diameter in segments 2, 3, 4, and 8 of the liver. Ultra-
sonography revealed low echoic lesions in segments 2
(13 mm in diameter) and 3 (8 mm in diameter) of the
liver. On contrast-enhanced ultrasonography using perflu-
butane, these lesions showed enhancement in the arterial
phase, subsequent washout in the portal phase, and de-
fects in the Kupffer phase. On contrast-enhanced CT,
these nodules showed ring enhancement in the arterial
phase and subsequent washout in the portal phase. In
addition, small nodules with the same enhancement pat-
tern were identified in segments 4 and 8 (Fig. 1). CT arter-
ial portography revealed nodular perfusion defects, and
CT hepatic arteriography revealed strong enhancement in
the early phase and ring enhancement in the late phase.
Magnetic resonance imaging (MRI) showed low intensity
on T1 weighted images, slightly high intensity on T2
weighted images, and high intensity on diffusion-weighted
images. On gadolinium-ethoxybenzyl-diethylenetriamine
pentaacetic acid (Gd-EOB-DTPA)-enhanced dynamic
MRI, the nodules showed ring enhancement in the arterial
phase and defects in the hepatocyte phase (Fig. 2). The pa-
tient also underwent whole-body positron emission
tomography-computed tomography, and all lesions had
standardized uptake values up to 4.6.
Because of atypical imaging findings, these tumors could
not be definitively diagnosed. The differential diagnosis in-
cluded hepatocellular carcinoma (HCC), metastatic liver
tumor (unknown primary origin), malignant lymphoma,
inflammatory pseudotumor, and pseudolymphoma. We
performed laparoscopic limited resection of segments 2, 3,
4, and 8 of the liver.
On visual examination of the resected liver specimens,
the tumors appeared well circumscribed and ash colored
(Fig. 3). On histopathological examination of the tumors,
many aggregated lymphoid follicles were noted with ger-
minal centers consisting of lymphocytic or plasmacytic
cells without atypia along with fibrocollagenous and hya-
linized stroma. The lymphoid follicles varied in size and
shape, and the germinal centers included small or large
lymphoid cells and tingible body macrophages. On im-
munohistochemical examination of the tumors, CD3-
positive cells were mainly localized in the parafollicular
area, and CD20 and 79a immunostaining was positive in
B follicles, while Bcl-2 staining was negative (Fig. 4).
Thus, the possibility of well-defined follicular lymphoma
was excluded, and pseudolymphoma of the liver was fi-
nally diagnosed. The patient has had no signs of recur-
rence for 6 months after the surgery.
Discussion
We reported the case of a patient with pseudolym-
phoma of the liver. Pseudolymphoma is a nodular le-
sion considered to result from a reactive immunological
response; however, the etiology of pseudolymphoma is
yet unknown [1]. It was first described in the lungs by
Saltzstein et al. in 1963 as a lymphocytic tumor associ-
ated with inflammation and with no evidence of sys-
temic dissemination [12]. Pseudolymphoma of the liver
is rare and was first reported by Snover et al. in 1981
[13]. Pseudolymphoma is defined histologically as the
aggregation of lymphoid follicles typically with reactive
Fig. 1 Contrast-enhanced computed tomography showing a nodule with ring enhancement in the arterial phase and subsequent washout in
the portal phase in segments 2, 3 (arrow), 4, and 8 of the liver
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hyperplasia of germinal centers showing proliferation of
polyclonal lymphocytes without atypia.
We reviewed the PubMed database from 1985 to
2014, using the keywords “liver,” “pseudolymphoma,”
and “lymphoid hyperplasia,” and we found 50 cases of
pseudolymphoma of the liver. These cases and our case
are summarized in Table 1. The mean age of the patients
was 58.9 years (range, 27–85; median, 60). Of the 51
cases, 5 (9.8 %) involved male patients and 46 involved
female patients (90.2 %). Among the 51 cases, 14
(27.4 %) had malignant diseases, including gastric cancer
[14–17], colon cancer [2, 18, 19], uterine/ovarian cancer
[20], renal cell carcinoma [21, 22], pancreatic cancer
[17], common bile duct cancer [23], and HCC [24].
Therefore, the pathogenesis of pseudolymphoma of the
liver with an associated malignant tumor may be related
to an immunological abnormality caused by the ma-
lignant tumor itself. However, we cannot confirm the
Fig. 2 Magnetic resonance imaging (MRI) showing a nodule with slight high intensity on a T2-weighted image and high intensity on a diffusion-
weighted image. Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced dynamic MRI showing a nodule with defects in the
hepatocyte phase in segments 2, 3 (arrow), 4, and 8 of the liver
Fig. 3 Image of a resected liver specimen showing a well-circumscribed, ash-colored tumor (a). On histological analysis, many aggregated lymphoid
follicles are seen with germinal centers consisting of lymphocytic or plasmacytic cells without atypia (b: scale bar, 25 μm, c: scale bar 10 μm)
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relationship between the presence of a pseudolymphoma
of the liver and a malignant tumor. This association may
be found frequently on incidental image examinations in
patients with malignant diseases.
Because pseudolymphoma is a lymphoid reaction, it has
been suggested that immunological dysregulation is asso-
ciated with pseudolymphoma [24]. Among the 51 cases
reviewed, 11 (22.2 %) had extrahepatic autoimmune dis-
eases, including Sjogren’s syndrome in 4 cases [25, 26],
autoimmune thyroiditis in 4 cases [24, 27–29], Takayasu
aortitis in 1 case [24], antiphospholipid syndrome in 1
case, and CREST syndrome (limited cutaneous form of
systemic scleroderma) in 1 case [1]. However, the present
patient did not have any autoimmune disease.
Among the 51 cases reviewed, 14 (27.5 %) had chronic
liver diseases, including primary biliary cirrhosis in 6
cases [1, 16, 24, 26, 30], viral hepatitis in 6 cases [24, 31,
32], and nonalcoholic steatohepatitis in 2 cases [33, 34].
Pseudolymphoma has been reported to develop after
interferon treatment for chronic hepatitis [31, 35]. This
finding supports the inflammatory nature of the lesion.
Moreover, lymphoid follicles are generally not identified
in the portal area of a normal liver but are found in a
liver with chronic hepatitis. Therefore, pseudolymphoma
of the liver has been reported to be associated with
hepatitis [24, 32]. However, the present patient did not
have any liver disease, including chronic hepatitis.
Imaging findings of pseudolymphoma resemble those
of other vascular tumors of the liver, such as HCC,
cholangiocarcinoma, and metastatic liver tumor; there-
fore, preoperative diagnosis of pseudolymphoma of the
liver is extremely difficult with imaging studies alone. In
terms of preoperative imaging findings, it has been re-
ported that most pseudolymphomas appear as low
echoic lesions with or without well-defined margins on
ultrasonography and as lesions having a low density on
plain CT [36]. In this case, the lesions showed defects in
the Kupffer phase on contrast-enhanced ultrasonography
using perflubutane. Perflubutane is phagocytosed by
macrophages, including Kupffer cells. A pseudolym-
phoma is a non-malignant tumor and lymphoid hyper-
plasia, but pseudolymphoma lesions in the liver replace
normal liver tissue. Therefore, these lesions have fewer
macrophages, including Kupffer cells, than normal liver
tissue, and these lesions may demonstrate a defect in the
Kupffer phase. Additionally, the lesions have variable
density on contrast CT, and many show enhancement in
the early phase and wash out in the late phase [32, 37].
On MRI, most of the lesions show low intensity on T1-
weighted images, high intensity on T2-weighted images,
hyperintensity on diffusion-weighted images, and hy-
pointensity on T1-weighted images in the hepatocyte
phase with Gd-EOB-DTPA enhancement [37]. Pseudo-
lymphoma of the liver may mimic a primary or metastatic
hepatic malignancy radiologically, especially in patients
with chronic hepatitis or internal malignancies. Among
the 51 reviewed cases, 19 had been misdiagnosed with
HCC preoperatively. Our patient did not have any risk
Fig. 4 Immunohistochemical analysis of the tumor. CD3-positive cells are mainly localized in the parafollicular area, and CD20 and CD79a immunostaining
is positive in B follicles, while Bcl-2 staining is negative (scale bar, 25 μm)
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factors for HCC. Additionally, the patient’s liver was not
cirrhotic and the levels of tumor markers were within nor-
mal limits. However, CT and MRI revealed multiple tu-
mors with ring enhancement. Therefore, malignancy could
not be excluded. We considered hepatic biopsy; however,
we believed that it would be insufficient to obtain an ac-
curate diagnosis and there was a possibility of needle im-
plantation of malignant tumor cells. Therefore, we decided
to perform hepatectomy without biopsy.
Histologically, pseudolymphoma consists of hyperplastic
lymphoid follicles, lymphocytes, and other inflammatory
cells, and an accurate diagnosis of pseudolymphoma relies
on immunohistochemical analysis [38]. Immunohisto-
chemical staining shows positive results for CD3, CD4,
and CD8 (T cell markers) and CD20 and CD79a (B cell
markers), indicating the polyclonality of the tumor. Add-
itionally, CD20 positive B cells are predominantly located
within the lymphoid follicles, and CD3 positive T cells are
predominantly located in the peri and interfollicular areas.
However, the lymphocytes within the germinal centers are
negative for Bcl-2, indicating the reactive and nonneoplas-
tic nature of the tumor [20].
The difference between pseudolymphoma and malig-
nant lymphoma is significant. Although the precise eti-
ology and pathogenesis of pseudolymphoma remain
unknown, its prognosis is much better than that of ma-
lignant lymphoma, especially follicular lymphoma. Fol-
licular lymphoma includes atypical cells and shows
monoclonal proliferation. Additionally, Bcl-2 expression
in lymphoid follicles is distinct for follicular lymphoma.
Moreover, in situ hybridization demonstrates intermixed
kappa and lambda light chains within interfollicular
plasma cells. DNA analysis helps to distinguish these le-
sions from those capable of malignant clonal lympho-
proliferation by ruling out monoclonal rearrangements
of immunoglobulin heavy chains or T cell receptor beta
and gamma genes [32].
Conclusions
In conclusion, pseudolymphoma of the liver should be
considered in the differential diagnosis of small hepatic
tumors, especially in female patients and patients with
no risk factors for hepatocellular carcinoma. Because it
is difficult to preoperatively distinguish pseudolym-
phoma from malignant tumors and metastases on the
basis of imaging findings, careful follow-up of patients is
essential and surgical intervention should be the choice
of treatment on suspicion of malignancy.
Consent
Consent was obtained from the patient for the publica-
tion of this case report.
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N = 51
Age, years 58.9 (27–85)
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Renal cell carcinoma 2
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Common bile duct cancer 1
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Associated liver disease 14 (27.5 %)
PBC 6
Chronic viral hepatitis 6
NASH 2
Preoperative diagnosis 41 (described)
HCC 19




Data are presented as mean (range), number (percentage), or number
HCC hepatocellular carcinoma, PBC primary biliary cirrhosis, NASH nonalcoholic
steatohepatitis, CCC cholangiocellular carcinoma
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